Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02366195 · ClinicalTrials.gov registry record · Phase 2
Single-arm Trial to Evaluate the Role of the Immune Response to Talimogene Laherparepvec in Unresected Melanoma
A Phase 2 study, sponsored by Amgen.
- Completed
- Registry status
- Phase 2
- Development phase
- 112
- Enrollment target
NCT02366195 is a Phase 2 study that has completed, run by Amgen. The registered enrollment target is 112 participants.
The verdict
NCT02366195, a Phase 2 study, has completed, sponsored by Amgen.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 112 participants
- Enrollment target
Study Summary
The study is a phase 2, multi centered, single arm study designed to evaluate the correlation between cluster of differentiation 8-positive (CD8+) cell density and objective response rate in adults with unresected stage IIIB to IVM1c melanoma. This study will also evaluate the safety and tolerability profile of talimogene laherparepvec.
Interventions
- DRUG Talimogene Laherparepvec
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 112 participants |
| Start Date | 2015-04-07 |
| Est. Completion | 2020-12-25 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02366195
The ClinicalTrials.gov registry entry for NCT02366195 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 112 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Talimogene Laherparepvec is the first listed.
NCT02366195 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02366195 about?
NCT02366195 is a clinical study titled "Single-arm Trial to Evaluate the Role of the Immune Response to Talimogene Laherparepvec in Unresected Melanoma". The study is a phase 2, multi centered, single arm study designed to evaluate the correlation between cluster of differentiation 8-positive (CD8+) cell density and objective response rate in adults with unresected stage IIIB to IVM1c melanoma. This study will also evaluate the safety and tolerabilit...
What is the current status of trial NCT02366195?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 112 participants. The study started on 2015-04-07. Estimated completion is 2020-12-25.
What interventions are being tested in trial NCT02366195?
The interventions under investigation include: Talimogene Laherparepvec (DRUG).
Who is sponsoring clinical trial NCT02366195?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.